ArticleBMC complementary medicine and therapies2025
Inhibitory effects of the flavonoids extracted from Pollen Typhae on palmitic acid-induced NLRP3 inflammasome activation in macrophages involving AMPK-mediated lipid metabolism.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanistic insights into natural product-driven modulation of NLRP3-inflammasome signalling in metabolic syndrome.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPollen Typhae (PT), a traditional Chinese medicine herb utilized in diabetes management, exerts anti-inflammatory effects through its flavonoids, yet the active constituents and mechanisms remain unclear.
methodsPT total flavone (PTF) was extracted from PT and identified the compounds by UHPLC-MS. Network pharmacology and molecular docking were used to predict the underlying targets and anti-inflammatory mechanisms of PTF. The prediction was validated in RAW264.7 macrophages. IL-1β and IL-18 in culture supernatants were analyzed by ELISA. The protein and gene expression were checked by western blotting and Real-time PCR, respectively. Intracellular ROS production was detected by DCFH-DA method. Intracellular lipids were analyzed by ELISA and Enzyme assay. The Caspase-1 activity was evaluated by bioluminescent method.
resultsPTF was identified 47 flavonoid compounds, including typhaneoside (TYP). Network pharmacology and molecular docking indicated that the flavonoid compounds might regulate inflammatory response, fatty acid metabolism, and the NOD-like receptor, AMPK pathways. PTF and TYP inhibited palmitic acid (PA)-induced NLRP3 inflammasome activation in lipopolysaccharide-primed RAW264.7 macrophages, leading to decreased secretion of IL-1β and IL-18. Furthermore, PTF and TYP improved intracellular lipid metabolism in PA-induced macrophages, indicating decreased free fatty acid and triglyceride contents, reduced protein expression of CD36, PPARγ, FAS, DGAT1, and CPT-1, as well as declined ROS with increased ATP production. Additionally, PTF and TYP increased the p-AMPK/AMPK ratio and upstream p-LKB1/LKB ratio. Activated AMPK, in turn, ameliorated lipid metabolism dysfunction, thus abolishing PA-induced ROS production and NLRP3 inflammasome activation. Antioxidant and improving lipid metabolism by suppressing ACC also inhibited NLRP3 inflammasome activation, respectively. Importantly, AMPK inhibition attenuated or abolished the inhibitory effects of PTF or TYP on ROS production, IL-1β and IL-18 secretion, and Caspase-1 activity.
conclusionThe findings highlight the ability of PTF and its active component TYP to inhibit PA-induced NLRP3 inflammasome activation in macrophages involving AMPK-mediated lipid metabolism, implying the potential use of PT flavonoid compounds as anti-diabetic inflammation lead compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.